Drs Jacob Sands and Shawn Regis discuss the risks and benefits of lung cancer screening.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969532). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

Resources

National Lung Screening Trial https://www.cancer.gov/types/lung/research/nlst

Lung Cancer: Screening, 1996 https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening-1996

NELSON Lung Cancer Screening Study https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3266562/

Early Lung Cancer Detection in High Risk Individuals (MILD) https://clinicaltrials.gov/ct2/show/NCT02837809

Screening for Lung Cancer With Low-Dose Computed Tomography: An Evidence Review for the U.S. Preventive Services Task Force https://www.ncbi.nlm.nih.gov/books/NBK568573/

Appendix A Table 5. Recommendations for Lung Cancer Screening With LDCT https://www.ncbi.nlm.nih.gov/books/NBK568579/table/appa.tab5/?report=objectonly

ALA Press Release https://www.lung.org/media/press-releases/new-sbts-psa-1

Lung CT Screening Reporting & Data System (Lung-RADS) https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/Lung-Rads

Outcomes of Positive and Suspicious Findings in Clinical CT Lung Cancer Screening and the Road Ahead https://pubmed.ncbi.nlm.nih.gov/34818144/

Lung Cancer Incidence and Mortality With Extended Follow-up in the National Lung Screening Trial https://www.jto.org/article/S1556-0864(19)30473-3/fulltext

Lung Screening Benefits and Challenges: A Review of The Data and Outline for Implementation https://www.jto.org/article/S1556-0864(20)30993-X/fulltext

American Thoracic Society and American Lung Association Implementation Guide for Lung Cancer Screening https://www.lungcancerscreeningguide.org/

Rescue Lung Society https://rescuelung.org/

Lung Cancer Screening Resources https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/saved-by-the-scan/resources

Go2 Foundation for Lung Cancer https://go2foundation.org/

Drs Jacob Sands and Pasi Jänne discuss the effectiveness of biomarkers and targeted therapies for lung cancer.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969533). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US health care professionals.

Resources

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma https://www.nejm.org/doi/full/10.1056/nejmoa0810699

The Value of Next-Generation Sequencing in Patients With Non-Small Cell Lung Cancer https://www.medscape.org/viewarticle/975903

ctDNA Shows Promise for Assessing Lung Cancer Treatment Response https://www.medscape.com/viewarticle/965587

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer https://www.nejm.org/doi/10.1056/NEJMoa2005653

Structure-Based Classification Predicts Drug Response in EGFR-Mutant NSCLC https://www.nature.com/articles/s41586-021-03898-1

Targeting Uncommon EGFR Mutations in Advanced NSCLC https://reference.medscape.com/recap/952720

Afatinib Prescribing Information https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Gilotrif/Gilotrif.pdf?DMW_FORMAT=pdf

Amivantamab Prescribing Information https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT-pi.pdf

Mobocertinib Prescribing Information https://content.takeda.com/?contenttype=pi&product=exkivity&language=eng&country=usa&documentnumber=1

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer https://www.nejm.org/doi/10.1056/NEJMoa1713137

Real-World Incidence and Impact of Pneumonitis in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors: a Multi-institutional Cohort Study https://jitc.bmj.com/content/10/6/e004670.long

Drs Jacob Sands and Jared Weiss discuss immunotherapy, including the importance of genomic testing, recent studies, new regimens, and the future of lung cancer treatment.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969534). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US health care professionals.

Resources

Severe Immune-Related Adverse Events Are Common With Sequential PD-(L)1 Blockade and Osimertinib https://www.annalsofoncology.org/article/S0923-7534(19)31165-2/fulltext

Pembrolizumab Versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1606774

Pembrolizumab Versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32409-7/fulltext

Cemiplimab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With PD-L1 of At Least 50%: A Multicentre, Open-Label, Global, Phase 3, Randomised, Controlled Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-67362100228-2/fulltext

Cemiplimab-rwlc for First-Line Treatment of NSCLC With High PD-L1 Expression https://ascopost.com/issues/may-10-2021/cemiplimab-rwlc-for-first-line-treatment-of-nsclc-with-high-pd-l1-expression/

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1801005

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1810865

Adjuvant Atezolizumab After Adjuvant Chemotherapy in Resected Stage IB-IIIA Non-Small-Cell Lung Cancer (IMpower010): A Randomised, Multicentre, Open-Label, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02098-5/fulltext

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC https://www.nejm.org/doi/10.1056/NEJMoa1716948

IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC https://www.jto.org/article/S1556-0864(21)02322-4/fulltext

First-Line Nivolumab plus Ipilimumab Combined With Two Cycles of Chemotherapy in Patients With Non-Small-Cell Lung Cancer (CheckMate 9LA): An International, Randomised, Open-Label, Phase 3 Trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30641-0/fulltext

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1910231

FDA Approves Nivolumab plus Ipilimumab for First-Line mNSCLC (PD-L1 Tumor Expression ≥1%) https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-plus-ipilimumab-first-line-mnsclc-pd-l1-tumor-expression-1

Clinical and Genomic Characteristics of Pts With Durable Benefit From Immune Checkpoint Inhibitors (ICI) in Advanced Non-Small Cell Lung Cancer (aNSCLC). https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9048?af=R

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1809064

Durvalumab plus Platinum–Etoposide Versus Platinum–Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32222-6/fulltext

A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) (DeLLphi-301) https://clinicaltrials.gov/ct2/show/NCT05060016